Project
SB-3799
SB-3799 is an innovative medicinal product utilizing intelligent granules with programmable release of Saccharomyces Boulardii in the human gastrointestinal tract.
Project Goal
The goal of SB-3799 is to develop an innovative Active Pharmaceutical Ingredient (API), as well as finished products containing the innovative API. The project focuses on developing technology for obtaining intelligent granules with programmable release of Saccharomyces Boulardii at a specific location in the human gastrointestinal tract. The result of the project will be a unique API form on a global scale. A characteristic feature of the product will be the release of the active substance in the terminal segments of the small intestine and in the large intestine of humans. The developed technology will enable the minimization of disadvantages of products obtained using currently known technologies.
Project Assumptions
The project concept is the result of collaboration between ASLAB Science and the scientific community, as well as a meta-analysis of scientific data available in the global literature regarding methods for increasing the viability of probiotic microorganisms and conducting preliminary research on the possibility of obtaining granules with controlled release in the terminal segments of the gastrointestinal tract. Within the project, a multi-phase technology for coating microgranules in a fluidized bed is being developed. The innovation of this technology lies in calibrating the API microgranules, coating them in a fluidized bed using the first polymer, and then using a solution of the second polymer. Polymers used in the process of coating API microgranules constitute an innovative solution of the company and cannot be disclosed at this stage, including the manufacturing technology.
Our product:
Our product will have a significant impact on the transformation of the global market. Saccharomyces boulardii yeast is used in the prevention of diarrhea that may occur during antibiotic therapy or while traveling. Additionally, it is used to treat diarrhea associated with the use of vancomycin or metronidazole. The company will develop products based on Saccharomyces boulardii with confirmed effectiveness in the treatment of various types of diarrhea in both children and adults. There is currently a lack of medication in the Polish and European markets that contains yeast released only in the intestine, bypassing the destructive action of gastric juice. A medication will be developed in which the dose of Saccharomyces boulardii will be reduced, thanks to significantly reduced yeast mortality after passing through the stomach, which will translate into the possibility of reducing the medication dose while maintaining the same or greater number of yeast cells reaching the large intestine compared to traditional medications.
Geographical transformation:
Due to the fact that the developed product will exhibit significantly greater stability during storage compared to lyophilized yeast, which has been used in commercial products and can be stored at temperatures not exceeding 25°C, the new product may generate new markets in Asian and African countries where such probiotics are not available. The development of a new modified API and, based on it, new medicinal products will contribute to the geographical transformation of the probiotic drug market by opening up new areas for development that have not previously had such medicinal products based on Saccharomyces boulardii yeast.
Back to project list
Learn more about our ongoing projects and the range of services we offer.
Get in touch with us
